Cutera (CUTR) Raised to Hold at Zacks Investment Research

Zacks Investment Research upgraded shares of Cutera (NASDAQ:CUTR) from a strong sell rating to a hold rating in a research note published on Wednesday.

According to Zacks, “Cutera Inc designs, develops, manufactures and markets the CoolGlide family of products for use in laser and other light-based aesthetic applications. The original CoolGlide CV provides permanent hair reduction on all skin types. The second generation CoolGlide Excel incorporated features that added the capability to treat a variety of vascular lesions, which include facial telangiectasia, spider and reticular leg veins. The CoolGlide Vantage added non-ablative skin therapy to the range of applications offered by the system. “

A number of other research analysts have also weighed in on CUTR. Stifel Nicolaus decreased their price objective on Cutera from $55.00 to $45.00 and set a hold rating on the stock in a report on Wednesday, August 8th. ValuEngine lowered Cutera from a strong-buy rating to a buy rating in a report on Wednesday, August 8th. BidaskClub lowered Cutera from a buy rating to a hold rating in a report on Thursday, September 20th. Stephens decreased their price objective on Cutera from $40.00 to $24.94 and set a sell rating on the stock in a report on Friday, October 5th. Finally, Sidoti set a $50.00 price target on Cutera and gave the stock a buy rating in a report on Friday, October 5th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and three have given a buy rating to the company’s stock. The stock presently has an average rating of Hold and a consensus price target of $39.24.

Shares of CUTR stock opened at $18.13 on Wednesday. Cutera has a fifty-two week low of $17.94 and a fifty-two week high of $56.05.

Cutera (NASDAQ:CUTR) last announced its quarterly earnings data on Tuesday, November 6th. The medical device company reported $0.11 earnings per share for the quarter, beating analysts’ consensus estimates of $0.03 by $0.08. The company had revenue of $40.60 million for the quarter, compared to analyst estimates of $40.03 million. Cutera had a negative return on equity of 0.50% and a net margin of 11.16%. The firm’s revenue for the quarter was up 6.4% on a year-over-year basis. During the same quarter last year, the firm posted $0.42 EPS. Equities analysts predict that Cutera will post -0.29 EPS for the current year.

Hedge funds and other institutional investors have recently bought and sold shares of the company. Piedmont Investment Advisors LLC purchased a new position in shares of Cutera during the 2nd quarter worth $128,000. SG Americas Securities LLC purchased a new position in shares of Cutera during the 2nd quarter worth $154,000. United Services Automobile Association purchased a new position in shares of Cutera during the 2nd quarter worth $208,000. Assenagon Asset Management S.A. purchased a new position in shares of Cutera during the 3rd quarter worth $263,000. Finally, Los Angeles Capital Management & Equity Research Inc. purchased a new position in shares of Cutera during the 2nd quarter worth $347,000.

About Cutera

Cutera, Inc, a medical device company, designs, develops, manufactures, markets, and services laser and other energy based aesthetics systems worldwide. The company offers enlighten platform, a laser system that is used for tattoo removal, as well as for the treatment of benign pigmented lesions; excel HR platform, a hair removal solution for various skin types; and truSculpt, a high-powered radio frequency platform designed for deep tissue heating.

Featured Article: Why do companies engage in swaps?

Get a free copy of the Zacks research report on Cutera (CUTR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Cutera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cutera and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply